NTRB

Nutriband Inc. (NTRB) - 10-Q Summary for Period Ended October 31, 2025

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended October 31, 2025, and the nine months ended on that date. Nutriband Inc. is a Nevada corporation focused on developing transdermal pharmaceutical products, primarily utilizing its proprietary AVERSA abuse-deterrent technology. The company operates through two main segments: Pocono Pharmaceuticals (contract manufacturing and sales of goods) and 4P Therapeutics (research and development of pharmaceutical products). The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline (QoQ): Revenue for the three months ended October 31, 2025, decreased to $346,058 from $645,796 in the same period in 2024. This decline is attributed to a principal customer moving operations to Asia and the winding down of the main contract in the 4P Therapeutics segment.
• Expense Surge: Selling, General, and Administrative (SG&A) expenses increased significantly to $3,491,728 for the quarter (from $737,102 in 2024) and $6,071,320 for the nine months (from $2,554,155 in 2024). This increase is primarily driven by equity-based compensation expenses.
• Preferred Stock Dividend: A significant non-cash event occurred in July 2025 where the company issued 3,008,643 shares of Series A Convertible Preferred Stock as a dividend. The fair value of this dividend was recorded as a charge of $21,814,166, drastically increasing the net loss available to common stockholders for the nine-month period.
• Debt Settlement: The company settled $317,110 of debt by issuing 120,000 shares of common stock to the President in October 2025.

Guidance, Outlook, and Risks

• Going Concern: Management believes substantial doubt about the company's ability to continue as a going concern is alleviated by current cash levels ($5.3M) and the ability to raise capital, though the company has a history of operating losses.
• Product Development: The primary focus remains on the development of AVERSA Fentanyl. An agreement with Kindeva Drug Delivery was amended to reduce the remaining budget for NDA submission to $3.2 million, with a $3.0 million milestone payment due upon FDA approval.
• Management Change: CEO Gareth Sheridan stepped aside for three months (August–October 2025) to campaign for the Irish Presidency. Co-founder and Chairman Serguei Melnik assumed CEO responsibilities during this period.
• Internal Controls: The company disclosed that its disclosure controls and procedures are not effective due to material weaknesses, including a lack of segregation of duties and reliance on third-party consultants, though improvements are underway.
• Legal Proceedings: The company is a defendant in a lawsuit by Joseph Gunnar, LLC and Lucosky Brookman LLP seeking over $500,000 in damages. The company has filed counterclaims seeking $2,000,000. The case is currently in the discovery stage.

Investor Verification Checklist

• Preferred Stock Terms: Verify the conversion mechanics and dividend rights of the newly issued Series A Convertible Preferred Stock and its impact on future dilution.
• Equity Compensation: Review the valuation assumptions (Black-Scholes inputs) used for the significant stock-based compensation expenses ($2.6M+ in nine months) to ensure they are reasonable.
• Legal Exposure: Monitor the status of the Gunnar/LB lawsuit and the potential impact of the counterclaims on the company's financial position.
• Internal Control Remediation: Assess the timeline and effectiveness of the company's plan to remediate material weaknesses in internal controls over financial reporting.
• Capital Sufficiency: Confirm the company's ability to fund the remaining $3.2M Kindeva development budget and ongoing operations without immediate additional equity dilution.